Radiotherapy for Prostate Cancer: Hypofractionation of Radiation - Jason Efstathiou

June 14, 2016

In this edition of 5 for 5, Dr. Jason Efstathiou discusses the benefits of hypofractionation and the radiobiological potential for therapeutic gain in prostate cancer. Dr. Efstathiou reviews the NRG Oncology RTOG 0415, RTOG 0938 studies and the CHHiP Trial.  Results from these trials and other moderate hypofractionation trials lead to conclusions that hypofractionation is safe and effective and has other potential advantages over standard fractionation. 


Jason A. Efstathiou, MD, Phil
Associate Professor
Director, Genitourinary Division 
Department of Radiation Oncology 
Clinical Co-Director, Bertucci Center for GU Cancers
Massachusetts General Hospital